저자: 미상 · 외국인
요약 보기
결론: 케시 우드가 최근 매수한 1달러 이하가 아닌 10달러 미만 저가주 두 종목(908 Devices, Adaptive Biotechnologies)을 소개하며 상승 여력이 크다고 주장하는 영상이다. 케시 우드 전략 개요: ARK Invest 펀드는 팬데믹 기간 큰 수익을 냈으나 작년 약세장에서는 손실을 봤고, 기술·헬스케어·자동차 등 파괴적 혁신 기업에 일관되게 투자해 왔다. 908 Devices(MASS): 화학 분석·탐지 장비 회사로 휴대형 질량분석 장비 mx-908이 주력이다. 최근 분기 매출 950만 달러로 예상을 85만 달러 웃돌았고, 휴대형 부문은 620만 달러(전년비 38% 증가)였다. EPS는 0.39달러로 예상 0.36달러 대비 양호했다고 언급. 연초 대비 13% 상승했으나 1년간 40% 하락. 908 Devices 근거 수치: ARK가 ARKG를 통해 3월 이후 456,342주 매수, 총 4,041,206주(약 3,475만 달러). 애널리스트 Daniel Arias는 매수 의견, 목표가 17달러, 현재가 8.60달러 대비 약 98% 상승 여력. 시장 컨센서스 전원 강력 매수, 평균 목표가 17달러. 매출 약 1배 수준의 밸류에이션 매력 언급. 908 Devices 리스크: 데스크톱 부문 부진, 바이오프로세싱 산업 역풍, 비정상 거래 패턴으로 변동성 확대 가능성. Adaptive Biotechnologies(ADPT): 면역 유전체 기반 상업 단계 바이오 기업. 주력 clonaseq 제품의 검사량이 전년비 57% 증가(12,079건), 1분기 매출 3,760만 달러로 예상 대비 69만 달러 상회. EPS 0.38달러로 예상 0.40달러에는 미달. 2023년 매출 가이던스 2.05~2.15억 달러(컨센서스 2.089억 달러 근사). 영업비용은 2022년 3.855억 달러보다 낮을 것으로 예상. ADPT 근거 수치: 올해 17% 하락. ARKG 통해 558,196주 매수, 총 9,554,319주(시가 약 6,258만 달러). JP Morgan Julia Chin은 비중확대(Overweight), 목표가 15달러, 현재가 6.55달러 대비 약 129% 상승 여력. 하반기 매출총이익률 개선 예상. ADPT 리스크: 단기 매출총이익률 압박. 종합 및 유의사항: 영상은 두 종목의 상승 여력과 우드의 확신을 강조하나, 시장 변동성·투자 위험을 언급하고 전문가 상담을 권하는 문구도 포함. 영상 말미 Mumu 증권계좌 개설 시 무료 주식 최대 16주 제공 광고 포함(스폰서).
다듬은 글
welcome to simple investing Secrets your go-to source for the best stocks to buy in in today's highly anticipated video we are diving deep into the world of investing with none other than the legendary Kathy Wood brace yourself as we unveil her most coveted picks the secret bargain stocks that come with a jaw-dropping Twist they're all priced under ten dollars if you thought finding hidden gems was challenging wait till you see these game-changing opportunities hand-picked by one of the most successful investors of our time so get ready to discover Kathy Woods untapped Treasure Trove as we delve into the strategies analysis and potential of these remarkable stocks buckle up for an eye-opening ride that could reshape your Investment Portfolio forever we're also going to tell you how you can get free stocks to add to your Investment Portfolio so be sure to watch to the end before we get started we kindly ask that you like the let's get started renowned investor Kathy Wood known for her distinctive investment approach has been instrumental in delivering substantial returns to investors in our Arc invest ETFs During certain periods notably amid the pandemic nevertheless her strategy has also led to losses during downturns like last year's bear Market throughout her career what is consistently favored disruptive companies in various sectors such as technology Healthcare and the automotive industry even in challenging times she has displayed an unwavering commitment to this investment philosophy regardless of individual opinions on her stock choices what has demonstrated the courage to remain steadfast in her convictions even when facing adversity in her recent shopping spree the CEO of Arc invest has identified two stocks that align with her preferred profile they possess transformative potential and are currently trading at prices that may be too compelling to overlook Wall Street analysts have identified these stocks as having significant upside potential and their prices are below ten dollars let's delve deeper into these investment opportunities number one 908 devices ticker m-a-s-s the first stock that would recommends is 908 devices a disrupter in the field of chemical analysis and detection Technologies this company specializes in the development of innovative handheld and desktop devices that facilitate real-time on-site chemical analysis its Cutting Edge Products leverage high pressure Mass spectrometry technology enabling the Swift identification and quantification of various substances in complex mixtures this technology finds applications across multiple Industries including Safety and Security life sciences and energy where accurate and timely chemical analysis is of Paramount importance one of 908 devices Flagship products the mx-908 is a handheld battery-powered Mass Spec device designed to rapidly analyze gas liquid and solid materials with unidentified identities in the most recent quarter 908 devices reported solid performance with its handheld segment accounting for the majority of sales the segment generated 6.2 million dollars representing a 38 year-over-year increase overall the company achieved total top-line revenue of 9.5 million dollars surpassing the forecast by 0.85 million dollars albeit falling short of analysts projected earnings per share of 39 cents compared to the anticipated 36 Cents while the stock has gained 13 year-to-date a broader perspective reveals a different story with a 40 decline over the past year despite this downward trajectory wood finds the reduced price attractive and has acquired 456 342 shares through our Arc genomic Revolution ETF ticker arkg since March as a result the fund now holds 4041 206 Mass shares valued at over 34.75 million dollars stifle analyst Daniel Arias views the stock favorably due to its appealing valuation arya's acknowledges 908 devices solid performance in the first quarter with a handheld business surpassing expectations and offsetting the challenges faced by the desktop business which aligns with broader headwinds experienced in the bioprocessing industry arya's notes that 908 devices has exhibited unusual trading patterns within his coverage Universe potentially leading to additional volatility throughout the year nevertheless he recommends the stock for investors exploring the small and mid-cap space emphasizing its trading at approximately 1X sales in the company's healthy balance sheet which provides a runway for several years Aria's assigns a buy rating to the stock and sets a price target of 17 implying a potential increase of approximately 98 from the current trading price of 8.60 the analyst consensus is unanimously positive with all analysts rating the stock as a strong buy at an average price target of 17 mirroring arya's objective number two adaptive biotechnologies ticker adpt would second notable investment is an Adaptive biotechnologies a pioneering commercial stage biotech company operating at the Forefront of immune-driven Medicine leveraging genetic data stored in the Adaptive immune systems of individuals the company has developed technologies that enable precise characterization and monitoring of immune responses adaptive biotechnology's clonaseq product employs Next Generation sequencing based assays to detect and monitor minimal residual disease in patients with hematologic Cancers the product has received FDA approval for use in multiple indications a 57 increase in clonusig volume to 12079 tests helped adaptive biotechnologies achieve revenue of 37.6 million dollars in the first quarter beating analysts Expectations by 0.69 million dollars however the company fell short of the projected EPS of 40 cents reporting 38 cents looking ahead the company reiterates its full year 2023 Revenue expectation anticipating a range between 205 million dollars and 215 million dollars slightly above the consensus estimate of 208.90 million dollars adaptive biotechnologies also expects its operating expenses including the cost of Revenue to be lower than its full year 2022 operating expenses of 385.5 million dollars despite underperforming the market with a 17 decline this year the stock has captured Woods interest she recently acquired 558 196 adpt shares through her Arc genomic Revolution ETF arkg increasing the fund's total adpt shares to 9554319 with a market value exceeding 62.58 million dollars Woods confidence in adaptive biotechnologies aligns with JP Morgan analyst Julia Chin's positive outlook chin describes the first quarter as another strong period for the company citing continued strength in clonacy and acknowledging near-term gross margin pressure while anticipating improvements in the second half of the year chin views adaptive biotechnologies as a unique player in immune-based Diagnostics and Therapeutics with a robust Pipeline and significant potential around drug Discovery milestones and royalties with an overweight buy rating chin assigns a price target of 15 implying a substantial one-year share appreciation of 129 percent from the current trading price of 6.55 cents Kathy Woods investment approach though unique and daring has proven highly effective in generating significant returns for investors during favorable market conditions while her strategy may have faced challenges and losses during Market downturns Wood's unwavering commitment to disruptive companies in various Industries has been a defining feature of her successful career the recent acquisitions of 908 devices and adaptive biotechnologies underpin Woods continued faith in companies with game-changing potential even if they are currently trading at lower prices both stocks offer Innovative Technologies with real world applications and Wall Street analysts see robust upside potential in these Investments as with any investment there are inherent risks and the Market's unpredictable nature may continue to impact the performance of these stocks nevertheless Kathy Woods conviction and her investment choices and her willingness to weather the storms staying true to her investing principles have earned her the admiration of many investors looking to follow in Wood's footsteps should exercise their due diligence carefully consider their risk tolerance and seek professional advice if necessary as the market evolves only time will tell how these particular investments will fare but Kathy Woods remarkable track record and unyielding Spirit continue to make her a compelling figure in the world of Finance we'd like to thank Mumu for sponsoring this video for a limited time you have an extraordinary opportunity to receive up to 16 free stocks when you open a brokerage account through our exclusive link Yes you heard it right up to 16 free stocks courtesy of Mumu don't miss out on this incredible deal simply click the link provided in our video description to unlock this special offer and claim your free stocks today take advantage of this fantastic promotion and embark on your investment Journey with a wealth of potential act now and seize the opportunity to secure up to 16 free stocks this offer won't last forever click the link in the description and get started today as always it is essential to do your due diligence before committing your hard-earned cash to buying stocks or investing in the market remember on s for watching and best of luck with your Investments
Comments 0